<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/3978</identifier>
				<datestamp>2020-02-06T08:45:09Z</datestamp>
				<setSpec>aabp:Post</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">In vitro susceptibility testing of ceftiofur against bovine mastitis pathogens isolated as part of an ongoing surveillance program (2002- 2010)</dc:title>
	<dc:creator xml:lang="en">Mullins, Lisa M.</dc:creator>
	<dc:creator xml:lang="en">Baillargeon, Paul</dc:creator>
	<dc:creator xml:lang="en">Johansen, Lacie</dc:creator>
	<dc:creator xml:lang="en">Lindeman, Cindy J.</dc:creator>
	<dc:subject xml:lang="en">antimicrobial susceptibility</dc:subject>
	<dc:subject xml:lang="en">mastitis</dc:subject>
	<dc:subject xml:lang="en">ceftiofur activity</dc:subject>
	<dc:subject xml:lang="en">coagulase-negative staphylococci</dc:subject>
	<dc:subject xml:lang="en">Strep. dysgalactiae</dc:subject>
	<dc:subject xml:lang="en">Escherichia coli</dc:subject>
	<dc:subject xml:lang="en">epidemiology</dc:subject>
	<dc:description xml:lang="en">Although many antimicrobial susceptibility reports have been published that include mastitis pathogens, few have compared susceptibility trends over time and geographical areas. In 2001, Pfizer Animal Health (PAH) initiated a pilot susceptibility surveillance program, and requested that six veterinary diagnostic laboratories submit bacterial pathogens isolated from naturally occurring mastitis infections for susceptibility testing at PAR. That year, 354 pathogens were tested. The program has grown and more than 1,200 isolates are tested each year. Results of ceftiofur activity against mastitis pathogens for the years 2002 to 2010 are reported here. SPECTRAMASTÂ® was approved in 2005 for the treatment of clinical mastitis associated with coagulase-negative staphylococci (CNS), Strep. dysgalactiae, and Escherichia coli in lactating dairy cattle and for the treatment of subclinical mastitis associated with Staphylococcus aureus, Strep. dysgalactiae, and Streptococcus uberis in dairy cattle at the time of dry off.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>2012-09-20</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/aabp/article/view/3978</dc:identifier>
	<dc:identifier>10.21423/aabppro20123978</dc:identifier>
	<dc:source xml:lang="en">American Association of Bovine Practitioners  Conference Proceedings; 2012; 271-272</dc:source>
	<dc:source>1079-9737</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/aabp/article/view/3978/3906</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2012 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
